Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Phase 2 Terminated 6 enrolled NYU Langone Health OSI Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm phase II study with a combination of Hycamptin® (topotecan) and erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent ovarian cancer previously treated with chemotherapy drug Hycamptin® (topotecan). Up to 30 patients will be enrolled in this study.

Timeline

Start: 2009-08
Primary completion: 2012-09
Completion: 2012-12

Outcome

Outcome not reported

Stopped (Business): “due to administrative issue and financial sponsor decision to suspend ovarian cancer studies”

Publications

Warner E, Liebes L, Levinson B, Downey A, Tiersten A, Muggia F. Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness. Oncologist. 2014 Mar;19(3):250. doi: 10.1634/theoncologist.2013-0398. Epub 2014 Feb 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	Topotecan	Small molecule	0.4 mg/m2	Other